Stockscreener 앱 받기
2.24
3.23%
0.07
전일 마감가:
$2.17
열려 있는:
$2.24
하루 거래량:
1.20M
Relative Volume:
1.27
시가총액:
$1.88M
수익:
$644.60K
순이익/손실:
$-9.87M
주가수익비율:
-0.00267
EPS:
-837.9618
순현금흐름:
$-9.02M
1주 성능:
-4.68%
1개월 성능:
-65.54%
6개월 성능:
-73.27%
1년 성능:
-94.84%
1일 변동 폭
$2.10
$2.30
1주일 범위
$2.06
$2.37
52주 변동 폭
$2.06
$92.00
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
BDRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
2.24 | 1.82M | 644.60K | -9.87M | -9.02M | -837.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-08 | 개시 | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr 주식(BDRX)의 최신 뉴스
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update - Defense World
Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary - Yahoo Finance
Biodexa pharmaceuticals appoints Fiona Sharp as CFO and board member By Investing.com - Investing.com India
Biodexa pharmaceuticals appoints Fiona Sharp as CFO and board member - Investing.com
Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Expands By 298.4% - Defense World
Biodexa Pharmaceuticals prices 157,000 units at $3.28 in public offering - TipRanks
Biodexa Pharmaceuticals stock falls after $10 million public offering By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals stock falls after $10 million public offering - Investing.com
Biodexa prices $10 million public offering of units and warrants - Investing.com
Biodexa prices $10 million public offering to fund development programs - Investing.com
Biodexa prices $10 million public offering to fund development programs By Investing.com - Investing.com UK
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Biodexa Pharmaceuticals (NASDAQ:BDRX) Shares Down 53.8% – Time to Sell? - Defense World
Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold - ts2.tech
Wall Street analysts’ outlook for Biodexa Pharmaceuticals Plc ADR (BDRX) - setenews.com
Biodexa Pharmaceuticals (NASDAQ: BDRX) outlines major unit deal with complex zero-cash warrants - Stock Titan
Biodexa enrolls first European patients in phase 3 FAP trial By Investing.com - Investing.com South Africa
Biodexa enrolls first European patients in phase 3 FAP trial - Investing.com
EBIT per share of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP - TradingView
[424B3] Biodexa Pharmaceuticals Plc Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Biodexa activates first European site for phase 3 FAP trial By Investing.com - Investing.com India
Biodexa activates first European site for phase 3 FAP trial - Investing.com
Biodexa Pharmaceuticals plc (BDRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Price Down 0.4% – What’s Next? - Defense World
[POS AM] Biodexa Pharmaceuticals Plc SEC Filing - Stock Titan
Total debt per share of Biodexa Pharmaceuticals plc Sponsored ADR – BER:5MP - TradingView
What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN
Holdings of Biodexa Pharmaceuticals Plc ADR (BDRX) are aligned with the stars - setenews.com
Biodexa receives EMA approval for phase 3 FAP treatment trial - Investing.com India
Biodexa (NASDAQ: BDRX) sets first EU enrollment for 4Q 2025 after EMA CTA approval - Stock Titan
Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Price Up 5.7% – Time to Buy? - Defense World
Biodexa Pharmaceuticals (NASDAQ:BDRX) Given Sell (E+) Rating at Weiss Ratings - Defense World
Why Did Biodexa Pharmaceuticals' Stock Drop After-Hours Despite Big Gain During Regular Trading? - inkl
Biodexa Hosts Breakfast Symposium on FAP Mechanisms and Chemoprevention at CGA‑IGC in October 2025 - Stock Titan
Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Decreases By 53.3% - Defense World
Interim results for the six months ended June 30, 2025 - GlobeNewswire
Biodexa Pharmaceuticals reports 1H EPS (GBP0.0002) vs. (GBP0.001) last year - TipRanks
Biodexa says requirement for financing represents ‘material uncertainty’ - TipRanks
First Patients Enrolled: Biodexa's Breakthrough FAP Treatment Advances to Pivotal Phase 3 Trial with $35M Backing - Stock Titan
Biodexa begins phase 3 trial of FAP treatment with $20M funding By Investing.com - Investing.com South Africa
Biodexa begins phase 3 trial of FAP treatment with $20M funding - Investing.com Canada
$7 Billion Untapped Market: Biodexa's eRapa Could Be First FDA-Approved Drug for Devastating FAP Disease - Stock Titan
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled - Finviz
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Nanotechnology Stocks To Watch Today – September 1st - Defense World
Biodexa announces enrollment of first two patients in Phase 3 Serenta trial - MSN
Biodexa Pharmaceuticals Plc Adr (BDRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):